Amgen Inc. (Amgen) is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It focuses its research and development activities on human therapeutics for in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. The Company’s marketed products include Neulasta, NEUPOGEN, ENBREL, Aranesp, EPOGEN, Sensipar/Mimpara, XGEVA and Prolia. In addition to its marketed products, the Company has various product candidates in mid-to late-stage of development. The Company markets its principal products primarily in the United States in cancer care, inflammation, nephrology and bone disease. As of February 17, 2014, the Company has 16 Phase III programs.